Results 181 to 190 of about 19,854 (197)

Third generation PCSK9-inhibitors

European Heart Journal, 2023
Ulrich Laufs, Matthias Blüher, Berend Isermann   +2 more
openaire   +3 more sources

Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans

Circulation, 2017
Gissette Reyes-Soffer, Tiffany Thomas, Stephen Holleran   +2 more
exaly  

The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism

Circulation, 2020
Nicholas A Marston, Yared Gurmu, Giorgio E M Melloni   +2 more
exaly  

Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH

EMBO Reports, 2011
Paola Lo Surdo, Matthew J Bottomley, Brian Hubbard   +2 more
exaly  

PCSK9-Inhibitoren

Herz, 2016
U. Laufs, F. Custodis, C. Werner
openaire   +1 more source

Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy

Circulation, 2018
Aruna D Pradhan, Aaron W Aday, Lynda M Rose   +2 more
exaly  

New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-κB pathway

Atherosclerosis, 2017
Zhi-Han Tang, Xi-Long Zheng
exaly  

A Small-Molecule Anti-secretagogue of PCSK9 Targets the 80S Ribosome to Inhibit PCSK9 Protein Translation

Cell Chemical Biology, 2016
Thomas N O'Connell, Markus Boehm, David Hepworth   +2 more
exaly  

PCSK9: Regulation and Target for Drug Development for Dyslipidemia

Annual Review of Pharmacology and Toxicology, 2017
Amy C Burke, Jacqueline S Dron, Robert A Hegele   +2 more
exaly  

Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: The PCSK9-REACT study

International Journal of Cardiology, 2017
Eliano Pio Navarese, Michalina Kołodziejczak, Max-Paul Winter   +2 more
exaly